Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:9551
Name smoldering myeloma
Definition A multiple myeloma that is a slow growing type of myeloma in which abnormal plasma cells results_in too much of a single type of monoclonal antibody.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myeloid neoplasm multiple myeloma smoldering myeloma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02279394 Phase II Dexamethasone Elotuzumab + Lenalidomide Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma Completed USA 0
NCT02886065 Phase I Durvalumab Durvalumab + PVX-410 Durvalumab + Lenalidomide + PVX-410 A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma Active, not recruiting USA 0
NCT02903381 Phase II Dexamethasone + Lenalidomide + Nivolumab Nivolumab + Lenalidomide + Dexamethasone In SMM Completed USA 0
NCT02960555 Phase II Diphenhydramine + Isatuximab + Methylprednisolone + Ranitidine Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma Recruiting USA 0
NCT03301220 Phase III Daratumumab + rHuPH20 A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 15
NCT03591614 Phase I DKK1 dendritic cell vaccine Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma Withdrawn USA 0
NCT03631043 Phase I Personalized cancer vaccine Personalized Vaccine in Treating Participants With Smoldering Multiple Myeloma Active, not recruiting USA 0
NCT03839459 Phase II Denosumab Denosumab for Smoldering Multiple Myeloma Active, not recruiting USA 0
NCT04270409 Phase III Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 14
NCT05055063 Phase I belantamab mafodotin-blmf A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma Recruiting USA 0
NCT05469893 Phase II Teclistamab Dexamethasone + Lenalidomide Immuno-PRISM (PRecision Intervention Smoldering Myeloma) Recruiting USA 0
NCT05597345 Phase II Selinexor Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma Recruiting USA 0
NCT05767359 Phase II Ciltacabtagene autoleucel + Cyclophosphamide + Fludarabine CAR- PRISM (PRecision Intervention Smoldering Myeloma) Recruiting USA 0
NCT06100237 Phase II Daratumumab + Teclistamab Daratumumab + Talquetamab-tgvs Teclistamab or Talquetamab in Combination With Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study) (REVIVE) Recruiting USA 0